{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T03:31:55Z","timestamp":1762918315521,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.vaccine.2021.12.014","type":"journal-article","created":{"date-parts":[[2021,12,11]],"date-time":"2021-12-11T01:33:56Z","timestamp":1639186436000},"page":"650-655","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers"],"prefix":"10.1016","volume":"40","author":[{"given":"Joana","family":"Oliveira-Silva","sequence":"first","affiliation":[]},{"given":"Teresa","family":"Reis","sequence":"additional","affiliation":[]},{"given":"Cristiana","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Ricardo","family":"Batista-Silva","sequence":"additional","affiliation":[]},{"given":"Ricardo","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Gilberto","family":"Marques","sequence":"additional","affiliation":[]},{"given":"V\u00e2nia","family":"Pacheco","sequence":"additional","affiliation":[]},{"given":"Tiago","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Alexandre","family":"Afonso","sequence":"additional","affiliation":[]},{"given":"V\u00edtor","family":"Pinheiro","sequence":"additional","affiliation":[]},{"given":"Luc\u00edlia","family":"Ara\u00fajo","sequence":"additional","affiliation":[]},{"given":"Fernando","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Isabel","family":"Antunes","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2021.12.014_b0005","doi-asserted-by":"crossref","unstructured":"Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline of immunological insights. Nat Rev Immunol. 2021;21:245\u201356. Available from: 10.1038\/s41577-021-00522-1.","DOI":"10.1038\/s41577-021-00522-1"},{"key":"10.1016\/j.vaccine.2021.12.014_b0010","first-page":"2439","article-title":"Safety and Immunogenicity of Two RNA-Based Covid-19","author":"Kitchin","year":"2021","journal-title":"Vaccine Candidates."},{"issue":"27","key":"10.1016\/j.vaccine.2021.12.014_b0015","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med."},{"issue":"118056","key":"10.1016\/j.vaccine.2021.12.014_b0020","first-page":"1","article-title":"Structural features of coronavirus SARS-CoV-2 spike protein: Targets for vaccination","volume":"257","author":"Sternberg","year":"2020","journal-title":"Life Sci."},{"key":"10.1016\/j.vaccine.2021.12.014_b0025","doi-asserted-by":"crossref","unstructured":"Poland GA, Ovsyannikova IG, Kennedy RB. SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates. Lancet [Internet]. 2020;396(10262):1595\u2013606. Available from: http:\/\/dx.doi.org\/10.1016\/S0140-6736(20)32137-1","DOI":"10.1016\/S0140-6736(20)32137-1"},{"key":"10.1016\/j.vaccine.2021.12.014_b0030","doi-asserted-by":"crossref","unstructured":"Geisen UM, Berner DK, Tran F, S\u00fcmb\u00fcl M, Vullriede L, Ciripoi M, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis Epub ahead print [Jully 7 2021]. 2021;(Cid):1\u20136.","DOI":"10.1136\/annrheumdis-2021-220272"},{"key":"10.1016\/j.vaccine.2021.12.014_b0035","doi-asserted-by":"crossref","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","author":"Turner","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2021.12.014_b0040","doi-asserted-by":"crossref","unstructured":"Ebinger JE, Fert-Bober J, Printsev I, Wu M, Sun N, Prostko JC, et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med [Internet]. 2021;27:981\u20134. Available from: 10.1038\/s41591-021-01325-6.","DOI":"10.1038\/s41591-021-01325-6"},{"key":"10.1016\/j.vaccine.2021.12.014_b0045","doi-asserted-by":"crossref","DOI":"10.1097\/TP.0000000000003784","article-title":"Poor Anti-SARS-CoV-2 Humoral and T-cell Responses After 2 Injections of mRNA Vaccine in Kidney Transplant Recipients Treated with Belatacept","author":"Chavarot","year":"2021","journal-title":"Transplantation"},{"key":"10.1016\/j.vaccine.2021.12.014_b0050","first-page":"1","article-title":"COVID-19 and kidney transplantation: Results from the TANGO International Transplant Consortium","volume":"00","author":"Cravedi","year":"2020","journal-title":"Am J Transpl."},{"key":"10.1016\/j.vaccine.2021.12.014_b0055","first-page":"1","article-title":"Reduced humoral response to mRNA SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients without prior exposure to the virus","volume":"00","author":"Grupper","year":"2021","journal-title":"Am J Transpl."},{"key":"10.1016\/j.vaccine.2021.12.014_b0060","doi-asserted-by":"crossref","unstructured":"Kageyama T, Ikeda K, Tanaka S, Taniguchi T, Igari H, Onouchi Y, et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine in 2015 healthcare workers in a single tertiary referral hospital in Japan. medRxiv [Preprint] [Internet]. 2021;1\u201316. Available from: https:\/\/medrxiv.org\/cgi\/content\/short\/2021.06.01.21258188.","DOI":"10.1016\/j.cmi.2021.07.042"},{"key":"10.1016\/j.vaccine.2021.12.014_b0065","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1001\/jama.2021.4385","article-title":"Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients","volume":"325","author":"Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2021.12.014_b0070","doi-asserted-by":"crossref","unstructured":"JP G, JR V, A R-N, M C. No TitleEfficacy of hepatitis B vaccination and revaccination and factors impacting on response in patients with inflammatory bowel disease. Am J Gastroenterol. 2012;107(10):1460\u20136.","DOI":"10.1038\/ajg.2012.79"},{"issue":"5","key":"10.1016\/j.vaccine.2021.12.014_b0075","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1016\/j.jaci.2020.03.017","article-title":"Influence of immune aging on vaccine responses","volume":"145","author":"Gustafson","year":"2020","journal-title":"J Allergy Clin Immunol."},{"issue":"January","key":"10.1016\/j.vaccine.2021.12.014_b0080","first-page":"1","article-title":"Aging, Immunity, and COVID-19: How Age Influences the Host Immune Response to Coronavirus Infections ?","volume":"11","author":"Bajaj","year":"2021","journal-title":"Front Physiol."},{"issue":"7","key":"10.1016\/j.vaccine.2021.12.014_b0085","doi-asserted-by":"crossref","first-page":"E257","DOI":"10.1002\/ajh.26185","article-title":"Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine","volume":"96","author":"Terpos","year":"2021","journal-title":"Am J Hematol."},{"key":"10.1016\/j.vaccine.2021.12.014_b0090","doi-asserted-by":"crossref","unstructured":"M\u00fclle L, Andr\u00e9e M, Moskorz W, Drexler I, Walotka L, Grothmann R. Age-dependent immune response to the Biontech\/Pfizer BNT162b2 COVID-19 vaccination. Clin Infect Dis. 2021;ciab381:1\u201318.","DOI":"10.1101\/2021.03.03.21251066"},{"issue":"25","key":"10.1016\/j.vaccine.2021.12.014_b0095","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1056\/NEJMoa2028436","article-title":"Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults","volume":"383","author":"Anderson","year":"2020","journal-title":"N Engl J Med."},{"issue":"832","key":"10.1016\/j.vaccine.2021.12.014_b0100","article-title":"Anti-SARS-CoV-2 Receptor-Binding Domain Total Antibodies Response in Seropositive and Seronegative Healthcare Workers Undergoing COVID-19 mRNA BNT162b2 Vaccination","volume":"11","author":"Salvagno","year":"2021","journal-title":"Diagnostics."},{"key":"10.1016\/j.vaccine.2021.12.014_b0105","doi-asserted-by":"crossref","unstructured":"Sasso B Lo, Giglio RV, Vidali M, Scazzone C, Bivona G, Gambino CM, et al. Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. Diagnostics [Internet]. 2021;11(1135). Available from: 10.3390\/diagnostics11071135.","DOI":"10.3390\/diagnostics11071135"},{"issue":"5","key":"10.1016\/j.vaccine.2021.12.014_b0110","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S1473-3099(10)70049-9","article-title":"The Xs and Y of immune responses to viral vaccines","volume":"10","author":"Klein","year":"2010","journal-title":"Lancet Infect Dis"},{"issue":"eabf8483","key":"10.1016\/j.vaccine.2021.12.014_b0115","article-title":"Kynurenic acid may underlie sex-specific immune responses to COVID-19","volume":"14","author":"Cai","year":"2021","journal-title":"Sci Signal"},{"key":"10.1016\/j.vaccine.2021.12.014_b0120","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.cophys.2018.03.010","article-title":"The evolution of greater humoral immunity in females than males: implications for vaccine efficacy","volume":"6","author":"Fink","year":"2018","journal-title":"Curr Opin Physiol"},{"issue":"3","key":"10.1016\/j.vaccine.2021.12.014_b0125","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/v13030422","article-title":"Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection","volume":"13","author":"Gobbi","year":"2021","journal-title":"Viruses."},{"issue":"8","key":"10.1016\/j.vaccine.2021.12.014_b0130","first-page":"8","article-title":"SARS-CoV-2 Antibody Responses in Infection-Naive or Previously Infected Individuals After 1 and 2 Doses of the BNT162b2 Vaccine","volume":"4","author":"Anderson","year":"2021","journal-title":"JAMA"},{"issue":"10279","key":"10.1016\/j.vaccine.2021.12.014_b0135","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/S0140-6736(21)00501-8","article-title":"Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals","volume":"397","author":"Manisty","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.vaccine.2021.12.014_b0140","first-page":"2100096","article-title":"Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 mRNA COVID-19 vaccine : real-world evidence from healthcare workers, Israel, December 2020 to January 2021","volume":"26","author":"Jabal","year":"2021","journal-title":"Euro Surveill."},{"key":"10.1016\/j.vaccine.2021.12.014_b0145","doi-asserted-by":"crossref","unstructured":"Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. Science (80-). 2021;371(587):1\u201313.","DOI":"10.1126\/science.abf4063"},{"key":"10.1016\/j.vaccine.2021.12.014_b0150","doi-asserted-by":"crossref","unstructured":"Salvagno GL, Henry BM, Pighi L, De Nitto S, Gianfilippi GL, Lippi G. Three-month analysis of total humoral response to Pfizer BNT162b2 mRNA COVID-19 vaccination in healthcare workers. J Infect [Internet]. 2021;88(2):10\u20131. Available from: https:\/\/doi.org\/10.1016\/j.jinf.2021.06.024.","DOI":"10.1016\/j.jinf.2021.06.024"},{"key":"10.1016\/j.vaccine.2021.12.014_b0155","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.bbrc.2020.10.108","article-title":"Humoral immune responses and neutralizing antibodies against SARS-CoV-2; implications in pathogenesis and protective immunity","volume":"538","author":"Carrillo","year":"2021","journal-title":"Biochem Biophys Res Commun."}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21016212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X21016212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:06:09Z","timestamp":1759403169000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X21016212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0264410X21016212"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.014","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2021.12.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}